Company: PMVP
Filing Date: 2025-04-25
Form Type: DEF 14A
Source: 0001140361-25-015610
Chunk: 29

Company: PMV Pharmaceuticals, Inc.
Filing Date: 2025-04-25
Form: DEF 14A
Chunk 29
---
     |             141,167 |
| Carol Gallagher, Pharm.D.    |     | —                |     |             128,000 |
| Arnold Levine, Ph.D.         |     | —                |     |             130,614 |
| Laurie Stelzer               |     | —                |     |             157,500 |

Scientific & Clinical Advisory Boards We have established scientific and clinical advisory boards composed of leading academic and industry scientists. We seek advice and input from these scientists on an ad hoc basis, individually or as a group, to provide scientific and clinical feedback and advice related to our research and development platform and programs. The members of our advisory boards consist of experts across a range of key disciplines relevant to our programs. Except for Drs. Baum, Heyman and Levine, who are members of our board of directors, our advisory board members are not our employees or directors and have no decision-making authority over our activities. Our advisory board members may have commitments to, or consulting or advisory contracts with, other entities that may limit their availability to us. In addition, our advisory board members may have arrangements with other companies to assist those companies in developing products or technologies that may compete with ours. All of our advisory board members are affiliated with other entities and devote only a small portion of their time to us. Our advisory board members receive cash and equity compensation based upon consulting services rendered. Effective September 1, 2021, Dr. Heyman agreed to waive any future scientific advisory compensation he is otherwise entitled to be paid for those services to us. Indemnification We have entered into an indemnification agreement with each of our directors and executive officers. The indemnification agreements and our amended and restated certificate of incorporation and amended and restated bylaws require us to indemnify our directors and executive officers to the fullest extent permitted by Delaware law. See “ Certain Relationships and Related Person Transactions—Indemnification of Directors and Officers.” Environmental, Social and Governance (ESG) Initiatives As a clinical-stage precision oncology company, we are rooted in our mission to fundamentally disrupt the course of cancer for patients with p53 gene mutations and other p53-related cancers. We believe integrating responsible environmental, social, and governance principles into our corporate strategy will drive sustainable value creation for our shareholders, employees, patients, and caregivers over the long term. We have formed an internal ESG Working Group with cross-functional senior leadership, and oversight by the nominating and corporate governance committee of our board of directors to oversee our